TDC
ABMD

Thompson Davis & Co’s Abiomed Inc ABMD Stock Holding History

Thompson Davis & Co’s Portfolio ABMD Stock Details ABMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-175
Closed -$33K – 753
2017
Q4 		$33K Sell
175
-128
-42% -$23.9K 0.08% 241
2017
Q3 		$51K Buy
+303
New +$45.8K 0.09% 234
2016
Q4 		– Sell
-460
Closed -$59K – 1234
2016
Q3 		$59K Hold
460
– – 0.1% 205
2016
Q2 		$50K Buy
+460
New +$45.8K 0.08% 246
2016
Q1 		– Sell
-250
Closed -$23K – 1193
2015
Q4 		$23K Hold
250
– – 0.03% 438
2015
Q3 		$23K Hold
250
– – 0.03% 428
2015
Q2 		$16K Hold
250
– – 0.02% 616
2015
Q1 		$18K Sell
250
-125
-33% -$6.79K 0.02% 565
2014
Q4 		$14K Buy
+375
New +$11.8K 0.02% 644

Other funds holding ABMD

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Winslow Capital Management
Winslow Capital Management Minneapolis, Minnesota $25.6B AUM 33.75% 1-Year Est. Return

Thompson Davis & Co's ABMD Position: Q1 2018 in Review

Thompson Davis & Co sold out of Abiomed Inc (ABMD) in Q1 2018, closing a stake of 175 shares — an estimated $33K sold.

Thompson Davis & Co first reported a position in ABMD in Q4 2014 and held it in 9 quarters. The position peaked at $59K in Q3 2016. 405 funds tracked by Wall St. Rank hold ABMD as of Q1 2018.

  • Thompson Davis & Co reported no remaining Abiomed Inc position as of Q1 2018 after selling out during the quarter.
  • Thompson Davis & Co sold 175 Abiomed Inc shares in Q1 2018, an estimated $33K.
  • Thompson Davis & Co first reported a position in Abiomed Inc in Q4 2014 and held it in 9 quarters.
  • Thompson Davis & Co's Abiomed Inc position peaked at $59K in Q3 2016.
  • 405 funds tracked by Wall St. Rank held Abiomed Inc as of Q1 2018.

Based on Thompson Davis & Co's 13F filing for Q1 2018, filed 2 May 2018.